Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jun;25(Suppl 1):S7-S8.
doi: 10.3747/co.25.4159. Epub 2018 Jun 13.

Progress in breast cancer-can we do better?

S F Dent  1
Affiliations
Editorial

Progress in breast cancer-can we do better?

S F Dent. Curr Oncol. 2018 Jun.
No abstract available

PubMed Disclaimer

References

    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics . Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017.
    1. Early Breast Cancer Trialists’ Collaborative Group Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39. doi: 10.1016/S1470-2045(17)30777-5. - DOI - PMC - PubMed
    1. Chia SK, Speers CH, D’yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9. doi: 10.1002/cncr.22867. - DOI - PubMed
    1. Baselga J, Campone M, Piccart M, et al. Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9. doi: 10.1056/NEJMoa1109653. - DOI - PMC - PubMed
    1. Sammons SL, Topping DL, Blackwell KL. hr+, her2–advanced breast cancer and cdk4/6 inhibitors: mode of action, clinical activity, and safety profiles. Curr Cancer Drug Targets. 2017;17:637–49. doi: 10.2174/1568009617666170330120452. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources